These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

814 related items for PubMed ID: 27227483

  • 1. Soluble and membrane-bound interleukin (IL)-15 Rα/IL-15 complexes mediate proliferation of high-avidity central memory CD8+ T cells for adoptive immunotherapy of cancer and infections.
    Hasan AN, Selvakumar A, Shabrova E, Liu XR, Afridi F, Heller G, Riviere I, Sadelain M, Dupont B, O'Reilly RJ.
    Clin Exp Immunol; 2016 Nov; 186(2):249-265. PubMed ID: 27227483
    [Abstract] [Full Text] [Related]

  • 2. Artificial antigen-presenting cells expressing AFP(158-166) peptide and interleukin-15 activate AFP-specific cytotoxic T lymphocytes.
    Sun L, Guo H, Jiang R, Lu L, Liu T, Zhang Z, He X.
    Oncotarget; 2016 Apr 05; 7(14):17579-90. PubMed ID: 27007051
    [Abstract] [Full Text] [Related]

  • 3. Interleukin-15 favors the expansion of central memory CD8+ T cells in ex vivo generated, antileukemia human cytotoxic T lymphocyte lines.
    Daudt L, Maccario R, Locatelli F, Turin I, Silla L, Montini E, Percivalle E, Giugliani R, Avanzini MA, Moretta A, Montagna D.
    J Immunother; 2008 May 05; 31(4):385-93. PubMed ID: 18391757
    [Abstract] [Full Text] [Related]

  • 4. Interleukin 15 promotes antigen-independent in vitro expansion and long-term survival of antitumor cytotoxic T lymphocytes.
    Lu J, Giuntoli RL, Omiya R, Kobayashi H, Kennedy R, Celis E.
    Clin Cancer Res; 2002 Dec 05; 8(12):3877-84. PubMed ID: 12473603
    [Abstract] [Full Text] [Related]

  • 5. IL-15/IL-15Ralpha-mediated avidity maturation of memory CD8+ T cells.
    Oh S, Perera LP, Burke DS, Waldmann TA, Berzofsky JA.
    Proc Natl Acad Sci U S A; 2004 Oct 19; 101(42):15154-9. PubMed ID: 15477598
    [Abstract] [Full Text] [Related]

  • 6. Treatment with soluble interleukin-15Ralpha exacerbates intracellular parasitic infection by blocking the development of memory CD8+ T cell response.
    Khan IA, Moretto M, Wei XQ, Williams M, Schwartzman JD, Liew FY.
    J Exp Med; 2002 Jun 03; 195(11):1463-70. PubMed ID: 12045244
    [Abstract] [Full Text] [Related]

  • 7. Avidity characterization of genetically engineered T-cells with novel and established approaches.
    Hillerdal V, Boura VF, Björkelund H, Andersson K, Essand M.
    BMC Immunol; 2016 Jul 13; 17(1):23. PubMed ID: 27411667
    [Abstract] [Full Text] [Related]

  • 8. Transpresentation of interleukin-15 by IL-15/IL-15Rα mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity.
    Van den Bergh J, Willemen Y, Lion E, Van Acker H, De Reu H, Anguille S, Goossens H, Berneman Z, Van Tendeloo V, Smits E.
    Oncotarget; 2015 Dec 29; 6(42):44123-33. PubMed ID: 26675759
    [Abstract] [Full Text] [Related]

  • 9. Identification of a novel HLA-A*24:02-restricted adenovirus serotype 11-specific CD8+ T-cell epitope for adoptive immunotherapy.
    Imahashi N, Nishida T, Ito Y, Kawada J, Nakazawa Y, Toji S, Suzuki S, Terakura S, Kato T, Murata M, Naoe T.
    Mol Immunol; 2013 Dec 29; 56(4):399-405. PubMed ID: 23911395
    [Abstract] [Full Text] [Related]

  • 10. Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo.
    Stoklasek TA, Schluns KS, Lefrançois L.
    J Immunol; 2006 Nov 01; 177(9):6072-80. PubMed ID: 17056533
    [Abstract] [Full Text] [Related]

  • 11. CD8 T cell priming in the presence of IFN-α renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy.
    Hervas-Stubbs S, Mancheño U, Riezu-Boj JI, Larraga A, Ochoa MC, Alignani D, Alfaro C, Morales-Kastresana A, Gonzalez I, Larrea E, Pircher H, Le Bon A, Lopez-Picazo JM, Martín-Algarra S, Prieto J, Melero I.
    J Immunol; 2012 Oct 01; 189(7):3299-310. PubMed ID: 22925929
    [Abstract] [Full Text] [Related]

  • 12. Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy.
    Goto T, Nishida T, Takagi E, Miyao K, Koyama D, Sakemura R, Hanajiri R, Watanabe K, Imahashi N, Terakura S, Murata M, Kiyoi H.
    J Immunother; 2016 Oct 01; 39(8):306-15. PubMed ID: 27548033
    [Abstract] [Full Text] [Related]

  • 13. A panel of artificial APCs expressing prevalent HLA alleles permits generation of cytotoxic T cells specific for both dominant and subdominant viral epitopes for adoptive therapy.
    Hasan AN, Kollen WJ, Trivedi D, Selvakumar A, Dupont B, Sadelain M, O'Reilly RJ.
    J Immunol; 2009 Aug 15; 183(4):2837-50. PubMed ID: 19635907
    [Abstract] [Full Text] [Related]

  • 14. Introduction of Genetically Modified CD3ζ Improves Proliferation and Persistence of Antigen-Specific CTLs.
    Miyao K, Terakura S, Okuno S, Julamanee J, Watanabe K, Hamana H, Kishi H, Sakemura R, Koyama D, Goto T, Nishida T, Murata M, Kiyoi H.
    Cancer Immunol Res; 2018 Jun 15; 6(6):733-744. PubMed ID: 29653982
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Peptide-beta2-microglobulin-major histocompatibility complex expressing cells are potent antigen-presenting cells that can generate specific T cells.
    Obermann S, Petrykowska S, Manns MP, Korangy F, Greten TF.
    Immunology; 2007 Sep 15; 122(1):90-7. PubMed ID: 17472719
    [Abstract] [Full Text] [Related]

  • 17. Induction of cytotoxic T-lymphocytes specific for malignant glioma by HLA dimer-based artificial antigen-presenting cells.
    Xiaobing J, Xiaoling L, Ruen L, Fangcheng Z, Hongyang Z.
    Cancer Biother Radiopharm; 2007 Dec 15; 22(6):826-35. PubMed ID: 18158774
    [Abstract] [Full Text] [Related]

  • 18. In vitro methods for generating CD8+ T-cell clones for immunotherapy from the naïve repertoire.
    Ho WY, Nguyen HN, Wolfl M, Kuball J, Greenberg PD.
    J Immunol Methods; 2006 Mar 20; 310(1-2):40-52. PubMed ID: 16469329
    [Abstract] [Full Text] [Related]

  • 19. Usefulness of IL-21, IL-7, and IL-15 conditioned media for expansion of antigen-specific CD8+ T cells from healthy donor-PBMCs suitable for immunotherapy.
    Chamucero-Millares JA, Bernal-Estévez DA, Parra-López CA.
    Cell Immunol; 2021 Feb 20; 360():104257. PubMed ID: 33387685
    [Abstract] [Full Text] [Related]

  • 20. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
    Wu F, Zhang W, Shao H, Bo H, Shen H, Li J, Liu Y, Wang T, Ma W, Huang S.
    Cancer Lett; 2013 Oct 10; 339(2):195-207. PubMed ID: 23791878
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.